Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Taiwan Bio Therapeutics's EBIT per Share for the
three
months ended in Dec. 2025 was NT$0.00.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-4.98.
During the past 3 years, the average EBIT per Share Growth Rate was -6.70% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -7.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Taiwan Bio Therapeutics's EBIT per Share or its related term are showing as below:
ROCO:6892'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -18.1 Med: -3.55 Max: 2.2
Current: -6.7
During the past 7 years, the highest 3-Year average EBIT per Share Growth Rate of Taiwan Bio Therapeutics was 2.20% per year. The lowest was -18.10% per year. And the median was -3.55% per year.
ROCO:6892's 3-Year EBIT Growth Rate is ranked worse than 77.83% of 1173
companies
in the Biotechnology industry
Industry Median: 15.6
vs ROCO:6892: -6.70
Taiwan Bio Therapeutics (ROCO:6892) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Taiwan Bio Therapeutics EBIT per Share Related Terms
Taiwan Bio Therapeutics EBIT per Share Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-4.98
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Taiwan Bio Therapeutics (ROCO:6892) has a EBIT per Share of NT$-4.98 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Taiwan Bio Therapeutics and its competitors. According to the industry distribution chart, Taiwan Bio Therapeutics ranks #913 out of 1173 companies in the Biotechnology industry, placing it in the top 77.8%.
Is Taiwan Bio Therapeutics' EBIT per Share too high?
Taiwan Bio Therapeutics' current EBIT per Share is NT$-4.98. Based on the distribution chart, Taiwan Bio Therapeutics ranks #913 out of 1173 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Taiwan Bio Therapeutics has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Taiwan Bio Therapeutics' EBIT per Share compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Taiwan Bio Therapeutics ranks #913 out of 1173 companies for EBIT per Share. This places Taiwan Bio Therapeutics in the lower half of its industry. The industry median EBIT per Share is 15.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Biotechnology company?
The median EBIT per Share among Biotechnology companies is 15.60, based on 1,173 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Taiwan Bio Therapeutics and its competitors. For the Biotechnology industry, the median EBIT per Share is 15.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Taiwan Bio Therapeutics's current EBIT per Share is NT$-4.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Taiwan Bio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics (ROCO:6892) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$14.62, compared to a current price of NT$25.95 — trading 77.5% above its estimated fair value. The current EBIT per Share is NT$-4.98. Taiwan Bio Therapeutics' overall GF Score™ is 22/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Taiwan Bio Therapeutics (ROCO:6892), the current EBIT per Share is NT$-4.98 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Taiwan Bio Therapeutics (ROCO:6892) Overvalued in 2026?
Based on GuruFocus' analysis, Taiwan Bio Therapeutics stock appears to be overvalued.
The current stock price of NT$25.95 is trading 77.5% above its estimated GF Value™ of NT$14.62.
GuruFocus considers Taiwan Bio Therapeutics to be Significantly Overvalued.
Key valuation signals for ROCO:6892:
EBIT per Share: NT$-4.98
GF Value™: NT$14.62 vs. price of NT$25.95 (77.5% above fair value)
No single metric tells the full story. See the ROCO:6892 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Taiwan Bio Therapeutics Inc is a regenerative medicine company specializing in the development of new genetically modified cell drugs. It is providing commissioned development and manufacturing (CDMO/CMO) services and inspection, analysis and development services for cellular medical products.
22GF Score
Get the complete analysis for ROCO:6892
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6892 has been successfully added to your 
